Index S&P 500
P/E 35.52
EPS (ttm) 2.53
Insider Own 0.42%
Shs Outstand 119.41M
Perf Week -1.31%
Market Cap 10.59B
Forward P/E 16.40
EPS next Y 5.48
Insider Trans -7.65%
Shs Float 117.37M
Perf Month -2.71%
Income 309.55M
PEG 4.62
EPS next Q 1.14
Inst Own 98.36%
Short Float 4.35%
Perf Quarter -21.70%
Sales 2.77B
P/S 3.82
EPS this Y 0.44%
Inst Trans 2.90%
Short Ratio 4.07
Perf Half Y -17.98%
Book/sh 63.96
P/B 1.40
EPS next Y 11.31%
ROA 2.30%
Short Interest 5.11M
Perf Year -18.51%
Cash/sh 9.66
P/C 9.30
EPS next 5Y 7.69%
ROE 3.82%
52W Range 88.53 - 129.50
Perf YTD -19.51%
Dividend Est. 0.27 (0.30%)
P/FCF 20.30
EPS past 5Y 3.37%
ROI 2.82%
52W High -30.63%
Beta 0.98
Dividend TTM 0.28 (0.31%)
Quick Ratio 2.99
Sales past 5Y 0.42%
Gross Margin 52.61%
52W Low 1.47%
ATR (14) 3.71
Dividend Ex-Date Jul 18, 2025
Current Ratio 3.58
EPS Y/Y TTM 78.53%
Oper. Margin 15.32%
RSI (14) 41.84
Volatility 2.94% 3.67%
Employees 11000
Debt/Eq 0.44
Sales Y/Y TTM 1.62%
Profit Margin 11.18%
Recom 2.05
Target Price 118.00
Option/Short Yes / Yes
LT Debt/Eq 0.44
EPS Q/Q 53.57%
Payout 11.63%
Rel Volume 1.04
Prev Close 93.58
Sales Surprise 0.61%
EPS Surprise 6.46%
Sales Q/Q 2.28%
Earnings Apr 28 BMO
Avg Volume 1.26M
Price 89.83
SMA20 -3.72%
SMA50 -8.90%
SMA200 -20.81%
Trades
Volume 1,300,352
Change -4.01%
Date
Action
Analyst
Rating Change
Price Target Change
May-01-25 Upgrade
UBS
Neutral → Buy
$115
Jan-10-25 Downgrade
Bernstein
Outperform → Mkt Perform
$130
Dec-13-24 Upgrade
BofA Securities
Neutral → Buy
$138
Oct-15-24 Upgrade
Barclays
Equal Weight → Overweight
$125 → $140
Aug-28-24 Initiated
Wells Fargo
Equal Weight
$130
Jul-08-24 Initiated
Leerink Partners
Outperform
$125
Jun-03-24 Resumed
Jefferies
Hold
$115
Jan-16-24 Downgrade
UBS
Buy → Neutral
$105 → $125
Jan-04-24 Upgrade
Evercore ISI
In-line → Outperform
$88 → $125
Dec-19-23 Initiated
Wells Fargo
Equal Weight
$95
Dec-13-23 Initiated
Wolfe Research
Peer Perform
Sep-28-23 Initiated
Bernstein
Outperform
$133
Jul-19-23 Initiated
Raymond James
Outperform
$145
May-23-23 Resumed
Goldman
Buy
$150
Show Previous Ratings
May-19-25 05:00PM
08:00AM
May-14-25 04:54PM
May-06-25 12:35AM
May-01-25 12:40AM
08:00AM
Loading…
Apr-30-25 08:00AM
Apr-29-25 05:57AM
03:02AM
01:20AM
(Thomson Reuters StreetEvents)
Apr-28-25 01:18PM
11:49AM
11:13AM
10:47AM
09:30AM
07:32AM
07:15AM
Loading…
07:15AM
06:09AM
(Associated Press Finance)
06:06AM
06:00AM
Apr-27-25 03:01AM
Apr-25-25 12:10PM
08:00AM
Apr-24-25 04:05PM
07:45AM
Apr-23-25 10:01AM
Apr-21-25 10:00AM
Apr-10-25 01:31PM
(Morningstar Research) -8.21%
Apr-03-25 08:00AM
05:21AM
Apr-02-25 08:00AM
07:47AM
Loading…
07:47AM
Mar-21-25 12:53PM
Mar-20-25 08:13PM
01:00PM
Mar-03-25 08:00AM
04:03AM
Feb-28-25 04:08AM
Feb-26-25 08:32AM
Feb-20-25 12:30PM
08:00AM
Feb-18-25 10:18AM
Feb-01-25 02:03AM
12:00AM
(Thomson Reuters StreetEvents)
Jan-31-25 03:48PM
03:10PM
09:30AM
07:10AM
06:19AM
(Associated Press Finance)
06:00AM
Jan-24-25 12:27PM
10:00AM
Jan-23-25 04:05PM
12:10PM
Jan-13-25 04:31PM
08:00AM
Jan-12-25 05:00PM
Jan-10-25 11:37AM
08:00AM
Jan-09-25 05:00AM
Dec-17-24 08:00AM
Dec-13-24 01:57PM
Dec-04-24 11:30AM
Nov-26-24 06:35AM
Nov-20-24 08:00AM
Nov-19-24 08:00AM
08:00AM
Nov-18-24 08:00AM
Nov-05-24 02:02AM
12:55AM
(Thomson Reuters StreetEvents)
Nov-04-24 12:22PM
09:30AM
07:10AM
06:09AM
(Associated Press Finance)
06:00AM
Oct-28-24 10:01AM
Oct-24-24 04:05PM
Oct-22-24 09:00AM
08:00AM
Oct-15-24 06:00AM
(The Wall Street Journal)
Oct-09-24 05:18PM
Oct-07-24 08:00AM
Oct-02-24 08:00AM
Aug-21-24 08:00AM
Aug-08-24 01:06AM
12:15AM
Jul-29-24 11:33PM
(Thomson Reuters StreetEvents) +9.07%
07:09PM
05:11PM
12:19PM
10:48AM
10:38AM
09:30AM
07:10AM
06:11AM
(Associated Press Finance)
06:00AM
Jul-26-24 12:47PM
Jul-25-24 04:15PM
Jul-22-24 10:01AM
Jul-19-24 12:10PM
Jul-09-24 08:00AM
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McMurry-Heath Michelle Director Feb 06 '25 Sale 119.49 1,970 235,395 3,021 Feb 07 04:05 PM McMurry-Heath Michelle Director Feb 06 '25 Proposed Sale 119.49 1,970 235,395 Feb 06 03:27 PM Goldberg Joel S Please See Remarks Jan 30 '25 Option Exercise 81.29 15,170 1,233,169 48,570 Jan 31 04:05 PM Goldberg Joel S Please See Remarks Jan 30 '25 Sale 126.73 15,170 1,922,513 33,400 Jan 31 04:05 PM Goldberg Joel S Officer Jan 30 '25 Proposed Sale 126.73 15,170 1,922,555 Jan 30 04:05 PM Vohra Tajinder S Please See Remarks Jan 07 '25 Option Exercise 81.29 5,492 446,445 25,144 Jan 08 04:05 PM Vohra Tajinder S Please See Remarks Jan 07 '25 Sale 116.81 5,492 641,543 19,652 Jan 08 04:05 PM Vohra Tajinder S Officer Jan 07 '25 Proposed Sale 116.81 5,492 641,539 Jan 07 04:58 PM Singh Prahlad R. Please See Remarks Dec 02 '24 Option Exercise 81.29 18,365 1,492,891 108,560 Dec 03 04:05 PM Singh Prahlad R. Please See Remarks Dec 02 '24 Sale 116.22 18,365 2,134,366 90,195 Dec 03 04:05 PM Singh Prahlad R. Officer Dec 02 '24 Proposed Sale 115.79 18,365 2,126,483 Dec 02 10:55 AM Vohra Tajinder S Please See Remarks Oct 09 '24 Sale 121.73 2,154 262,202 19,652 Oct 10 04:05 PM Vohra Tajinder S Officer Oct 09 '24 Proposed Sale 121.73 2,154 262,199 Oct 09 04:21 PM Vohra Tajinder S Please See Remarks Oct 08 '24 Sale 122.59 2,154 264,057 21,806 Oct 09 04:05 PM Vohra Tajinder S Please See Remarks Oct 07 '24 Sale 122.09 2,153 262,853 23,960 Oct 09 04:05 PM Vohra Tajinder S Officer Oct 08 '24 Proposed Sale 122.59 2,154 264,066 Oct 08 04:42 PM Vohra Tajinder S Officer Oct 07 '24 Proposed Sale 122.09 2,153 262,855 Oct 07 04:10 PM MICHAS ALEXIS P Director Aug 15 '24 Sale 118.62 850 100,827 7,770 Aug 16 04:05 PM MICHAS ALEXIS P Officer Aug 15 '24 Proposed Sale 117.65 850 100,000 Aug 15 09:53 AM Goldberg Joel S Please See Remarks Aug 07 '24 Sale 117.86 3,500 412,507 33,400 Aug 08 04:05 PM Goldberg Joel S Officer Aug 07 '24 Proposed Sale 117.86 3,500 412,514 Aug 07 04:59 PM Goldberg Joel S Please See Remarks Jun 07 '24 Sale 110.46 4,000 441,844 36,900 Jun 10 04:05 PM